Picture loading failed.

Pre-Made Bavituximab biosimilar, Whole Mab: Anti-Phosphatidylserine therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Bavituximab (PGN401) is a human-mouse chimeric monoclonal antibody against phosphatidylserine, which is a component of cell membranes that is exposed when a cell is transformed into solid tumor cancer cell or dies, and when cells are infected with hepatitis C.[3] The process of cell death is highly controlled and so there usually no immune response to phosphatidylserine but when bavituximab binds to it, the conjugate appears to stimulate an immune response in humans.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-051-1mg 1mg 3090
GMP-Bios-ab-051-10mg 10mg Inquiry
GMP-Bios-ab-051-100mg 100mg Inquiry
GMP-Bios-ab-051-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Pre-Made Bavituximab biosimilar, Whole Mab: Anti-Phosphatidylserine therapeutic antibody
INN Name Bavituximab
FormatWhole mAb
DerivationChimeric (Mouse/Human)
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2006
Year Recommended2007
CompaniesAvid Bioservices;IMV;Massachusetts General Hospital;Merck Sharp & Dohme;Peregrine Pharmaceuticals;University of Arizona;University of Texas Southwestern Medical Center;University of Texas M. D. Anderson Cancer Center
Conditions Approvedna
Conditions ActiveNon-small cell lung cancer;Glioblastoma;Liver cancer;Solid tumours
Conditions DiscontinuedBreast cancer;Malignant melanoma;Pancreatic cancer;Brain cancer;Hepatitis C;HIV infections;Rectal cancer;Viral haemorrhagic fevers;Influenza virus infections;Prostate cancer
Development Techna